Key result
Bradykinin significantly enhanced the release of noradrenaline in human atrium only when its enzymatic degradation was prevented by the ACE inhibitor captopril.
Population
Human and rat atrial slices
Comparison
Bradykinin in the presence of ACE inhibitor… vs Bradykinin in the absence of ACE inhibition
Design
Preclinical
Authors
Loading...
ACE inhibition may unmask bradykinin-mediated atrial noradrenaline release; hypothesis-generating for in vivo sympathetic effects.
ACE inhibition unmasks a sympathofacilitatory effect of bradykinin in human atrial tissue, likely via B2-receptor activation and prostaglandin release.
Rump et al. (1997) studied this question. Bradykinin with ACE inhibitor (captopril) vs. Bradykinin without ACE inhibition was evaluated on Stimulation-induced outflow of radioactivity (index of endogenous noradrenaline release). Bradykinin significantly enhanced the release of noradrenaline in human atrium only when its enzymatic degradation was prevented by the ACE inhibitor captopril.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: